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Poster Session II S297was to analyze the impact of CsA levels in the development of grade
2-4 aGVHD in the setting of allo-RIC in the first four weeks after
transplantation.
Patients and Methods: We included 156 consecutive patients [64
(41%) women], median age 52 (17-69) years, who underwent
HLA-identical sibling allo-RIC at a single institution. RIC included
fludarabine 150 mg/m2 plus busulfan 10 mg/kg (for myeloid malig-
nancies n 5 53) or melphalan 70-140 mg/m2 (lymphoid malignan-
cies n 5 103). GVHD prophylaxis was based on CsA plus
methotrexate (MTX) (n 5 121, 78%) or mychopenolate mofetil
(MMF) (n 5 35, 22%). CsA levels were measured at least twice
weekly during the first four weeks (or until discharge) and the dose
was adjusted to maintain blood levels between 200 and 300 ng/ml.
Results:As the use ofMTXvsMMFdid not impact on the incidence
of grades 2-4 aGVHD patients were analyzed together. The median
blood concentrations of CsA at 1st, 2nd, 3rd and 4th weeks after allo-
SCT were 134 (95 CI:10-183), 219 (95 CI: 54-261), 253 (95 CI: 53-
314) and 224 ng/ml (95 CI:30-411) respectively. The number of pa-
tients who were in the optimal range in the 1st, 2nd, 3rd and 4th
weeks after allo-RIC were 34/150 (22%), 92/154 (59%), 86/148
(58%) and 53/123 (56%). Sixty six patients developed grade 2-4
aGVHD for a cumulative incidence of 42% (95% CI 35-51%) at
a median of 38 (range:18-138) days after allo-SCT. In univariate
analysis the variables associated with a higher incidence of 2-4
aGVHDwere: male sex (p5 0.016), female to male donor-recipient
sex combination (p 5 0.05), and median CsA levels in the second (p
5 0.02) and third (p5 0.02) weeks. In multivariate analysis, the only
significant variables associated with higher 2-4 aGVHDwere female
to male donor-recipient sex combination (HR 2; p 5 0.01) and the
median CsA levels in the third week (HR 0.097, p 5 0.039).
Conclusion:The levels of CsA in the immediate post-transplant pe-
riod were suboptimal in almost 50% of patients. Low levels of CsA
were associated with higher incidence of grade 2-4 aGVHD. A
more stringent monitoring and modification of CsA in the early
phase post-Allo-RIC may be helpful to prevent aGVHD.396
ANALYSIS OF THE FLT3-ITD AND NPM1 MUTATIONS IN AML PATIENTS
WITH INTERMEDIATE RISK RECEIVING ALLOGENEIC STEM-CELL TRANS-
PLANTATION
Ogasawara, M., Yamakawa, T., Katsura, Y., Shima, K., Matsukawa, T.,
Kanaya, M., Minauchi, K., Nakata, M., Ota, S., Imai, K., Hirano, T.,
Kobayashi, N., Kiyama, Y. Sapporo Hokuyu Hospital, Sapporo, Japan
Background: Chromosomal abnormality is the most important
prognostic factor for AML patients. Recently, prognosis of cytoge-
netically normal AML patients has been reported to be affected by
the presence of fms-like tyrosine kinase 3 gene internal tandem
duplication (FLT3-ITD) and nucleophosmin 1 gene (NPM1)
mutations. In the present study, we analyzed retrospectively the
FLT3-ITD and NPM1 mutations in AML patients with cytogenet-
ically intermediate risk who received allo-SCT and we evaluated the
effect of the mutations on the outcome of allo-SCT.
Patients and Methods: 23 patients (11 males and 12 females) with
a median age of 46 years (range: 27-65) receiving allo-SCT between
2005 and 2009 whose BM samples were available were enrolled in
this study. Allo-SCT consisted of 10 matched siblings, 8 matched
unrelated donors and 5 unrelated cord blood. GVHD prophylaxis
included CsA/ short term MTX (10) or FK/short term MTX (13).
GenomicDNAwas extracted fromPBMCand amplified by PCRus-
ing specific primers. Analysis of FLT3-ITD or NPM1 exon 12 mu-
tations was carried out by either electrophoresis or direct DNA
sequencing.
Results: FLT3-ITD mutation was found in 5 patients (21.7%).
FLT3-ITD mutation occurred only in cytogenetically normal pa-
tients (positivity: 38.5%). On the other hand, NPM1 mutation was
found in 6 patients (26.1%). Acute GVHD above grade II was found
in 4 patients (57.1%)with FLT3-ITDmutationwhile only 3 patients
(20.0%) without FLT3-ITDmutation manifested the complication.
Frequency of acute GVHD above grade II was 33% and 41% in
NPM1 mutation positive and negative patients, respectively. All
the patients with FLT3-ITDmutation manifested relapse of the dis-
ease following allo-SCTwhile relapse occurred in 5 patients (33.3%)without FLT3-ITD mutation. However, there was no marked dif-
ference in relapse rate between patients with or without NPM1 mu-
tation (33% vs. 41%). Median period of overall survival was 0.184
and 1.619 years in FLT3-ITD mutation positive and negative pa-
tients, respectively.
Conclusions: It was demonstrated that the rate of both relapse and
acute GVHD was significantly higher in AML patients with FLT3-
ITD mutation compared to FLT3-ITDmutation negative patients.
NPM1 mutation exerted minimal effect on the incidence of acute
GVHD and relapse of the disease. These results suggested that
allo-SCT patients with cytogenetically intermediate risk can be
stratified to poor prognosis group if FLT3-ITD mutation is
identified.397
PLASMA CYTOKINE PROFILES AT DAY ZERO: MYELOABLATIVE CONDI-
TIONING EXHIBITS A MORE INFLAMMATORY PROFILE THEN REDUCED
INTENSITY CONDITIONING IN PEDIATRIC PATIENTS UNDERGOING
ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
Grimley, M.1, Rehman, N.1, Mellor Heinke, S.1, Villanueva, J.1,
Marsh, R.1, Bleesing, J.1, Mehta, P.1, Jordan, M.1, Kim, M.-O.2,
Li, D.2, Davies, S.1, Filopovich, A.1 1Cincinnatio Children’s Hospital
Medical Center, Cincinnati, OH; 2Cincinnati Children’s HospitalMedical
Center, Cincinnati, OH
While myeloablative conditioning (MAC) has been the conven-
tional preparative regimen for allogeneic stem cell transplant, re-
duced intensity conditioning (RIC) has increasingly been used,
especially in non-malignant conditions. MAC has been associated
with a cytokine storm that may contribute to graft versus host disease
(GVHD) while RIC has shown lower tissue damage which may lead
to a lower release of inflammatory cytokines. We hypothesized that
patients receiving MAC would express a more inflammatory subset
of plasma cytokines on Day Zero compared to patients receiving
RIC.
METHODS:Weprospectively collected samples on 52 consecutive
consented patients who underwent allogeneic transplantation at
Cincinnati Children’s Hospital Medical Center between December
2007 and October 2008. Blood samples were collected at Day 0.
Patient Characteristics are in Table 1.
Table 1.
RIC MACNumber of Patients 23 29
Patient Age -median
(range) years6.7 (0.6-17.9) 8.1 (0.8-19.4)Patient Gender 13 males/10 females 20 males/9 females
Diagnosis 23 non-malignant 12 malignant/17
non-malignantABio-Plex Pro Assay was used tomeasure plasma levels of GM-CSF,
G-CSF, IL-1b, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, IL-
13, IL-17, IFN-g, MCP-1, MIP-1b, TNF-a, IL-18, and MIF.
Plasma concentrations of sTNF-R1 were measured by ELISA. Sol-
uble IL-2 Receptor alpha (sIL2Ra) levels were measured using the
Immulite platform.
RESULTS: Wilcoxon rank sum test was used to compare the
plasma cytokine levels between the RIC and MAC groups. IL-6,
G-CSF, sIL-2Ra, IL-17 and IL-7 plasma levels were found to be dif-
ferent in the two groups (p # 0.05). We additionally analyzed 2
groups within the RIC cohort-10 patients received distal alemtuzu-
mab (between Days -22 and -13 pretransplant) and 12 patients re-
ceived proximal alemtuzumab (between Days -12 and -8
pretransplant). In this analysis, patients who received distal alemtu-
zumab have higher levels of the tested cytokines including IL-1b,
IL-6, IL-8, IFN-g, MIF and TNF-a (p # 0.05).
DISCUSSION:A pro-inflammatory cytokine profile (increased IL-
6, G-CSF and sIL-2Ra) is seen in MAC patients when compared to
RIC patients who have increased levels of differentiation (IL-17) and
growth (IL-7) cytokines. The timing of alemtuzumab prior to trans-
plant affects the cytokine profile on Day 0. Patients receiving distal
alemtuzumab have higher levels of the pro-inflammatory cytokines
S298 Poster Session II(IL-1b, IL-6, IL-8, IFN-g, MIF and TNF-a). We have observed
clinical differences in the rates of mixed chimerism and GVHD de-
pending on when the alemtuzumab is given. This data suggests that
the cytokine milieu may contribute to the development of GVHD
and Transplant Related Morbidity (TRM).
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OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLAN-
TATION IN COMMUNITY CANCER CENTERS: SINGLE INSTITUTION EXPE-
RIENCE
Khaled, Y., Beredo, L., McEntee, S., Fondaw, M., Villegas, M.,
Mountford, K., Reddy, V. Florida Cancer Institute, Orlando, FL
Variability in outcomes after hematopoietic stem cell transplanta-
tion (HCT) due to differences in health care delivery is traditionally
referred to as ‘‘center effect’’. Data analysis by CIBMTR demon-
strated improved day 100 survival after related donor (RD) HCT
with greater physician involvement in patient’s care regardless of
medical school affiliation. We hypothesized that the greater physi-
cian involvement in patient’s care at our community transplant cen-
ter would compensate for the lack of infrastructure available to
academic centers and result in comparable outcomes.We retrospec-
tively reviewed the medical records of 50 consecutive patients who
underwent matched unrelated (MUD) HCT (n 5 26) or RD HCT
(n 5 24) for hematological malignancies between August 2007 andTable 1. Patients characteristic
Number of patients 50 (100%)
Age Median 56 (Range 23-71)
Patients above the age of 55 27 (54%)
Patients below the age of 55 23 ( 46%)
Match related (RD) 23 (46%)
Mismatched related 5/6 1 (2%)
Matched unrelated (MUD) 22 (44%)








T-cell prolymphocytic leukemia 2 (4%)
CML (accelarated phase) 1 (2%)
HD 2 (4%)
Severe aplastic anemia 1 (2%)
Non Hodgkins lymphoma 3 (6%)
Multiple myeloma 3 (6%)
Stem cell source Peripheral stem cells 50 (100%)
Status at transplant
Complete remission -1 20 (40%)
Complete remission-2 9 (18%)
Progressive disease 7 (14%)
Persistent disease 14 (28%)
Prior Transplants
Autologous 7; non tandem (14%)
Allogeneic related 5 (10%)
Cytogenetics
High Risk 28 (56%)
Normal 19 (38%)
Not available 3 (6%)
Charlson Comorbidity Index
Score 0 7 (14%)
Score 1-2 10 (20%)
Score 3-4 20(40%)
Score 5 and above 13 (26%)
Conditioning Regimens
Full Intensity (FIC) 20 (40%)
Reduced Intensity(RIC) 21(42%)
Non Myeloablative (NMA) 9 (18%)
GVHD, graft versus host disease; OS, overall survival; DFS, disease free
survival; NRM, non relapse mortality; NMA, Flu/TBI, RIC, FluBU-2/Flu-
Mel, FIC FluBU-4/BUCY/CYTBIApril 2010. GVHD prophylaxis used was Tacrolimus/Methotrexate
or Tacrolimus/Mycophenolate. MUD HCT recipients recieved
ATG in addition. Twenty one (42%) and twenty eight patients
(56%) of cohort had progressive/persistent disease and high risk cy-
togenetics at time of transplant respectively. Thirty three patients
(66%) had Charlson Co-morbidity index of 3 or more. Patients
characteristic is shown in the table below.
OS at 100 days and 1 year were 86% and 67% respectively. There
was no statistical difference in OS between RD and MUD; (83% vs.
88% at day 100 and 74% vs. 64% at 1 year for RD and MUD recip-
ients respectively, P5 0.85). DFSwas 55% at 1year. Again, there was
no statistical significance difference in DFS between RD and MUD
at 1 year (P5 0.48). The cumulative incidence of relapse was 16% at
1 year (21% for RD and12% for MUD). We found no difference in
the cumulative incidence of NRMbetween RD andMUD recipients
at day 100 (12%). In contrast, NRM was higher at 1 year in MUD
recipients of 34% vs. 25% for the RD recipients. The overall cumu-
lative incidence of acute GVHD grade II-IV was 47.8% with inci-
dence of severe GVHD grade III/IV of 16%. The cumulative
incidence of chronic GVHD was 67.6%.
Conclusions: Allogeneic HCT outcomes in the community seem to
be comparable to outcomes reported in literature. In this single in-
stitution experience, despite the absence of direct cause and effect re-
lationship, the greater involvement of physicians in the patient’s care
may have contributed to the improved outcomes in this high risk co-
hort of patients. Community transplant centers may contribute in
the future to meet the increased demands for allogeneic HCT with
reasonable outcomes.
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PRELIMINARY RESULTS OF PHASE II TRIAL OF CLOFARABINEWITH PAR-
ENTERAL BUSULFAN (CLO/BU) FOLLOWED BY ALLOGENEIC RELATED
OR UNRELATED DONOR TRANSPLANTATION FOR THE TREATMENT OF
HEMATOLOGIC MALIGNANCIES
Agura, E.1,2, Berryman, R.B.1,2, Pineiro, L.1,2, Vance, E.1,2, Tadic-
Ovcina, M.1, Woelfel, R.G.1, Fay, J.1,2 1Charles A Sammons Cancer
Center, Baylor University Medical Center, Dallas, TX; 2Charles A
Sammons Cancer Center, Texas Oncology P.A., Dallas, TX
BACKGROUND: RIT regimens are common, but relapse remains
a problem. We proposed and tested a mid-intensity regimen using
clofarabine (CLO) with busulfan (BU).We hypothesized this combo
would be well tolerated and offer greater anti-leukemic efficacy than
existing RIT regimens.
METHODS:We enrolled 20 patients on this single IST, with AML
(10), ALL (1), CLL (1),MDS (2) andMDS-AML (6). 15 patients had
prior therapies. The regimenwas: CLO40mg/m2 iv daily x5, BU 3.2
mg/kg iv daily x2, followed by 1 rest day, followed byHSCT.Donors
were matched at A, B, C, DR, DQ usingDNA SBT or mid-res DNA
typing. Mismatch# 1 antigen was allowed. GVHD prophylaxis was
FK506 and MTX 5mg/m2 iv (d 1,3,6).
RESULTS: Endpoints included toxicity, engraftment, incidence/
severity of AGVHD, and disease response.
All patients experienced grade 4 hem tox.Median time to ANC re-
covery (18/20 patients used GCSF) was 13 days (d9 - d17). Engraft-
ment (. 80% donor chim. at d30) occurred in all patients by FISH
and/or STR. Selected tox. included; 2 patients - hand/foot syndrome
(1 Gr. 3, REL.); 1 resp. failure (Gr. 3 poss. REL) resolved com-
pletely; 5 patients - elevated ALT/AST (Gr.3-4, REL) resolving at
regimen completion; other tox. were#Gr. 2. TRMwas non-existent
in this study.
18 patients developed AGVHD by d100 – 83% grade 1-2; 17%
grade 3-4. No deaths attributed to AGVHD following study regi-
men.
Disease responses are: 11 (58%) patients, in relapse/active disease
prior to CLO/BU, achieved CR by d30. 7 (37%) patients in CR at
study entry, remained so at d30. 1 patient was N/E for disease re-
sponse at d30. 1 patient (w / CLL) achieved CR at d132. 7 (37%) pa-
tients relapsed (M. d120 (d60 – d699)). 12 (60%) patients expired (M.
d222 (d92 – d438)): cardiac arrest (1, d316); asp. pneumonia (1,
d158); TTP (1, d438); AGVHD - post DLI (1, d175); relapse (4,
M. d192 (d150 – d415)); persistent disease (1, d161); MSOF (1,
d92); ITP (1, d307); Pulmonary Embolus (1, d233). Of 19 evaluable
patients, 6 (32%) remain in remission with a median follow up of 946
days (31 months) (d396 – d1236).
